Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Livzon Pharmaceutical Group ( (HK:1513) ) is now available.
Livzon Pharmaceutical Group has issued a revised proxy form for its 2025 annual general meeting scheduled for 29 May 2026, replacing the original version solely to correct typographical and formatting issues without altering any substantive content. The original proxy form is now void, and shareholders who already submitted it are required to complete and resubmit the revised proxy form under the same submission methods and deadlines, with the company apologizing for any inconvenience caused.
The most recent analyst rating on (HK:1513) stock is a Sell with a HK$22.99 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
More about Livzon Pharmaceutical Group
Livzon Pharmaceutical Group Inc. is a China-based pharmaceutical company listed in Hong Kong, engaged in the research, production and sale of medicines and related healthcare products. The group operates in the broader healthcare sector, serving domestic and international markets through a portfolio of prescription drugs and other pharmaceutical offerings.
Average Trading Volume: 914,627
Technical Sentiment Signal: Hold
Current Market Cap: HK$31.03B
For detailed information about 1513 stock, go to TipRanks’ Stock Analysis page.